Top Industry Leaders in the Guillain-Barre Syndrome Market
Latest Guillain-Barre Syndrome Companies Update
March 2022: OpdualagTM (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered as a single intravenous infusion, has been approved by the United States Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.1 The approval is based on the RELATIVITY-047 Phase 2/3 study. The trial's primary goal, progression-free survival (PFS), was met, and Opdualag more than doubled the median PFS when compared to nivolumab alone. The following clinically significant immune-mediated adverse events occurred at a rate of 1% (unless otherwise specified) in patients who received OPDIVO monotherapy or OPDIVO in combination with YERVOY, or were reported in patients who received other PD-1/PD-L1 blocking antibodies. Some adverse responses, such as Guillain-Barré syndrome, have resulted in severe or fatal instances.
January 2023: Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today reported progress across its broad complement therapy portfolio and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated disorders. Annexon has focused resources and execution of its four flagship programs' late-stage development: Guillain-Barré syndrome (GBS), Huntington's disease (HD), geographic atrophy (GA), and ANX1502, a first-in-class oral small molecule. Complete extended enrollment in its current critical Phase 3 study for ANX005 in GBS patients - the first placebo-controlled trial in almost 40 years.List of Guillain-Barre Syndrome Key companies in the market
- Grifols (Spain)
- Baxter (U.S.)
- CSL Behring (U.S.)
- Akari Therapeutics Plc (U.S.)
- ANNEXON, INC. (U.S.)
- Curavac (Europe)
- Hansa Medical (Sweden)
- Vitality Biopharma (U.S.)
- Covidien Limited (Republic of Ireland)
- Natus Medical Inc. (U.S.)
- Electrical Geodesics Inc. (U.S.)